Drug Discovery World

JANUARY 30, 2024

Natalia Elizalde, Chief Business Development Officer, VIVEbiotech, says that Dr Naldini’s award represents the significant benefits and demonstrated safety of the therapies developed using lentiviral vectors that are being used for more and more clinical trials and more prevalent diseases.

Gene Therapy 72

Gene Therapy Manufacturing Gene Clinical Trials 72

pharmaphorum

DECEMBER 16, 2022

Dopavision, a DTx company in the eye health space, has brought on ophthalmology and neuroscience expert Dirk Sauer , a veteran of Novartis Pharma, to advise the company as it continues to develop MyopiaX, a digital therapeutic for childhood myopia control. AI and robotics hires. McKinnell, Jr. to support the company’s growth.

Behavioural Health 52

Behavioural Health Reagent Gene Therapy Production 52

Drug Discovery World

MAY 16, 2023

Investment landscape In 2023, Matthieu de Kalbermatten, CEO of CellProthera, looks forward to presenting the final safety and efficacy results of the company’s Phase II clinical trial, and for moving into Phase III. Lending to the time-to-clinic discrepancy, we also see increasing demands on manufacturing capacity for CGT reagents.”

Gene Therapy 52

Gene Therapy Gene Manufacturing Marketing 52

Drug Discovery World

DECEMBER 23, 2022

The 400,000 square-foot cGMP facility enables gene and cell therapy R&D programmes to advance IND filings and clinical trials. BRL-201 was developed using Quikin CART, BRL’s non-viral site-specific integration platform, which can produce CAR-T cell products using one-step, non-viral preparation. .

Gene Therapy 52

Gene Therapy Gene Reagent Clinical Trials 52

The Pharma Data

OCTOBER 14, 2020

A paper on the clinical trial results published in JAMA Oncology demonstrates the effectiveness of Savran Tech’s CTC detection technology with real world patients. BOSTON–( BUSINESS WIRE )– Savran Technologies Inc., BOSTON–( BUSINESS WIRE )– Savran Technologies Inc., About This Clinical Trial.

Clinical Trials 40

Clinical Trials Clinical Trials Trials Genome 40

Drug Discovery World

NOVEMBER 30, 2023

Lightcast is developing a novel, programmable microfluidic platform that allows precise and highly flexible control of individual microdroplets using software-generated light patterns. GSK has developed high-throughput mammalian and E.

Antibody 59

Antibody Protein Engineer In-Vivo 59

XTalks

OCTOBER 1, 2020

Xtalks spoke with WeiQi Lin, MD, PhD, executive vice president, research & development, and principal scientist at DURECT Corporation — a company focused on developing drugs and drug delivery methods in therapeutic areas with significant unmet need — about her transition from academia to industry. Key Moments.

Scientist 52

Scientist In-Vitro Research Life Science 52